Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

EGFR monoclonal antibody plus platinum-based chemotherapy

9 evidence topics · 6 sources

EXTREME efficacy in the label
EndpointCetuximab with platinum-based therapy and fluorouracilPlatinum-based therapy and fluorouracil
Participants“(n=222)”“(n=220)”
Median OS, months“10.1”“7.4”
OS hazard ratio (95% CI)“0.80 (0.64, 0.98)”Reference
Median PFS, months“5.5”“3.3”
PFS hazard ratio (95% CI)“0.57 (0.46, 0.72)”Reference
ORR“35.6%”“19.5%”